Characteristics of Pseudomonas aeruginosa infection in intensive care unit before (2007-2010) and after (2011-2014) the beginning of an antimicrobial stewardship program.

Antimicrobial stewardship & healthcare epidemiology : ASHE Pub Date : 2024-04-29 eCollection Date: 2024-01-01 DOI:10.1017/ash.2024.53
Alessio Strazzulla, Vladimir Adrien, Segla Robert Houngnandan, Sandra Devatine, Ouerdia Bahmed, Sarra Abroug, Sarra Hamrouni, Mehran Monchi, Sylvain Diamantis
{"title":"Characteristics of <i>Pseudomonas aeruginosa</i> infection in intensive care unit before (2007-2010) and after (2011-2014) the beginning of an antimicrobial stewardship program.","authors":"Alessio Strazzulla, Vladimir Adrien, Segla Robert Houngnandan, Sandra Devatine, Ouerdia Bahmed, Sarra Abroug, Sarra Hamrouni, Mehran Monchi, Sylvain Diamantis","doi":"10.1017/ash.2024.53","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the factors associated with <i>Pseudomonas aeruginosa</i> isolates in intensive care unit (ICU) before and after an antimicrobial stewardship program.</p><p><strong>Materials: </strong>Monocentric retrospective cohort study. Patients admitted to the ICU in 2007-2014 were included. Characteristics of <i>P. aeruginosa</i> patients were compared to overall ICU population. Clinical and microbiological characteristics of <i>P. aeruginosa</i> patients before (2007-2010) and after (2011-2014) the beginning of the AMP were compared.</p><p><strong>Results: </strong>Overall, 5,263 patients were admitted to the ICU, 274/5,263 (5%) had a <i>P. aeruginosa</i> isolate during their staying. In 2011-2014, the percentage <i>P. aeruginosa</i> isolates reduced (7% vs 4%, <i>P</i> ≤ .0001). Patients with <i>P. aeruginosa</i> had higher rates of in-hospital death (43% <i>vs</i> 20%, <i>P</i> < .0001) than overall ICU population. In 2011-2014, rates of multidrug-resistant (11% <i>vs</i> 2%, <i>P</i> = .0020), fluoroquinolone-resistant (35% vs 12%, <i>P</i> < .0001), and ceftazidime-resistant (23% vs 8%, <i>P</i> = .0009) <i>P. aeruginosa</i> reduced. Treatments by fluoroquinolones (36% vs 4%, <i>P</i> ≤ .0001), carbapenems (27% vs 9%, <i>P</i> = .0002), and third-generation cephalosporins (49% vs 12<i>%</i>, <i>P</i> ≤ .0001) before <i>P. aeruginosa</i> isolation reduced while piperacillin (0% vs 13%, <i>P</i> < .0001) and trimethoprim-sulfamethoxazole (8% vs 26%, <i>P</i> = .0023) increased. Endotracheal intubation reduced in 2011-2014 (61% vs 35%, <i>P</i> < .0001). Fluoroquinolone-resistance was higher in patients who received endotracheal intubation (29% vs 17%, <i>P</i> = .0197). Previous treatment by fluoroquinolones (OR = 2.94, <i>P</i> = .0020) and study period (2007-2010) (OR = 2.07, <i>P</i> = .0462) were the factors associated with fluoroquinolone-resistance at the multivariate analysis.</p><p><strong>Conclusions: </strong>Antibiotic susceptibility in <i>P. aeruginosa</i> isolates was restored after the reduction of endotracheal intubation, fluoroquinolones, carbapenems, and third-generation cephalosporins and the increased use of molecules with a low ecological footprint, as piperacillin and trimethoprim-sulfamethoxazole.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062793/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobial stewardship & healthcare epidemiology : ASHE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/ash.2024.53","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To investigate the factors associated with Pseudomonas aeruginosa isolates in intensive care unit (ICU) before and after an antimicrobial stewardship program.

Materials: Monocentric retrospective cohort study. Patients admitted to the ICU in 2007-2014 were included. Characteristics of P. aeruginosa patients were compared to overall ICU population. Clinical and microbiological characteristics of P. aeruginosa patients before (2007-2010) and after (2011-2014) the beginning of the AMP were compared.

Results: Overall, 5,263 patients were admitted to the ICU, 274/5,263 (5%) had a P. aeruginosa isolate during their staying. In 2011-2014, the percentage P. aeruginosa isolates reduced (7% vs 4%, P ≤ .0001). Patients with P. aeruginosa had higher rates of in-hospital death (43% vs 20%, P < .0001) than overall ICU population. In 2011-2014, rates of multidrug-resistant (11% vs 2%, P = .0020), fluoroquinolone-resistant (35% vs 12%, P < .0001), and ceftazidime-resistant (23% vs 8%, P = .0009) P. aeruginosa reduced. Treatments by fluoroquinolones (36% vs 4%, P ≤ .0001), carbapenems (27% vs 9%, P = .0002), and third-generation cephalosporins (49% vs 12%, P ≤ .0001) before P. aeruginosa isolation reduced while piperacillin (0% vs 13%, P < .0001) and trimethoprim-sulfamethoxazole (8% vs 26%, P = .0023) increased. Endotracheal intubation reduced in 2011-2014 (61% vs 35%, P < .0001). Fluoroquinolone-resistance was higher in patients who received endotracheal intubation (29% vs 17%, P = .0197). Previous treatment by fluoroquinolones (OR = 2.94, P = .0020) and study period (2007-2010) (OR = 2.07, P = .0462) were the factors associated with fluoroquinolone-resistance at the multivariate analysis.

Conclusions: Antibiotic susceptibility in P. aeruginosa isolates was restored after the reduction of endotracheal intubation, fluoroquinolones, carbapenems, and third-generation cephalosporins and the increased use of molecules with a low ecological footprint, as piperacillin and trimethoprim-sulfamethoxazole.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
抗菌药物管理计划启动前(2007-2010 年)和启动后(2011-2014 年)重症监护病房铜绿假单胞菌感染的特征。
目的:研究重症监护病房铜绿假单胞菌分离的相关因素:研究重症监护病房(ICU)在实施抗菌药物管理计划前后铜绿假单胞菌分离的相关因素:单中心回顾性队列研究。材料:单中心回顾性队列研究。将铜绿假单胞菌患者的特征与重症监护病房的总体情况进行比较。比较了 AMP 启用前(2007-2010 年)和启用后(2011-2014 年)铜绿假单胞菌患者的临床和微生物学特征:结果:共有5263名患者入住重症监护室,其中274人/5263人(5%)在住院期间分离到铜绿假单胞菌。2011-2014年,铜绿假单胞菌分离率有所下降(7% vs 4%,P ≤ .0001)。铜绿假单胞菌患者的院内死亡率(43% vs 20%,P < .0001)高于重症监护病房的总体死亡率。2011-2014年,耐多药(11% vs 2%,P = .0020)、耐氟喹诺酮(35% vs 12%,P < .0001)和耐头孢唑肟(23% vs 8%,P = .0009)铜绿假单胞菌的发病率有所下降。铜绿假单胞菌分离前使用氟喹诺酮类(36% vs 4%,P ≤ .0001)、碳青霉烯类(27% vs 9%,P = .0002)和第三代头孢菌素类(49% vs 12%,P ≤ .0001)治疗的情况减少,而使用哌拉西林(0% vs 13%,P < .0001)和三甲双胍-磺胺甲噁唑(8% vs 26%,P = .0023)治疗的情况增加。2011-2014年,气管插管率有所下降(61% vs 35%,P < .0001)。接受气管插管治疗的患者对氟喹诺酮类药物的耐药性更高(29% vs 17%,P = .0197)。曾接受氟喹诺酮类药物治疗(OR = 2.94,P = .0020)和研究时间(2007-2010年)(OR = 2.07,P = .0462)是多变量分析中与氟喹诺酮耐药相关的因素:结论:在减少气管插管、氟喹诺酮类、碳青霉烯类和第三代头孢菌素以及增加使用哌拉西林和三甲双氨-磺胺甲噁唑等生态足迹小的分子后,铜绿假单胞菌分离株的抗生素敏感性得到恢复。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
0
期刊最新文献
Effect of automated identification of antimicrobial stewardship opportunities for suspected urinary tract infections. Impacts of risk-stratified inpatient penicillin allergy label delabeling on subsequent antimicrobial spectrum index and costs. Successful adaptation of an initiative to reduce unnecessary antibiotics for acute respiratory infections across two Veteran Affairs ambulatory healthcare systems. Trends in antibiotic utilization for patients hospitalized with COVID-19 with and without signs of sepsis. Assessing a safety climate tool adapted to address respiratory illnesses in Canadian hospitals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1